RxDoctor Payments Data

Ramalingeswara Yalamanchi, MD

Internal Medicine · Southgate, MINPI 1033263884

Payments from drug & device makers

$208in general payments, 2019–2025

Across 5 payments — averaging $41.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$125
  • E.r. Squibb & Sons, L.L.C.$33
  • Novo Nordisk$27
  • Exact Sciences$23

What the payments were for

  • Food & beverage$208100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$208 in reported general payments places this provider in the 50th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$226,859
Medicare patients
258
Services billed
2,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin272$343,084
EliquisApixaban272$331,204
Trelegy ElliptaFluticasone/Umeclidin/Vilanter280$316,118
Humira PenAdalimumab19$207,055
MounjaroTirzepatide92$129,840
OzempicSemaglutide63$91,203
FarxigaDapagliflozin Propanediol52$60,467
XareltoRivaroxaban56$41,595
Lantus SolostarInsulin Glargine,hum.Rec.Anlog117$29,422
JanuviaSitagliptin Phosphate29$27,832
ProliaDenosumab14$23,261
Tresiba Flextouch U-100Insulin Degludec19$20,098
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$18,830
Novolog FlexpenInsulin Aspart37$15,714
Atorvastatin Calcium986$13,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$27$91,20363 claims
Johnson & JohnsonXarelto$125$41,59556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southgate

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →